AOD-9604 Global Regulatory Status: What Women Need to Know Before Using This Peptide

What Is AOD-9604 and Why Does Its Regulatory Status Matter for Women

AOD-9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, specifically amino acids 176 to 191 of the GH sequence. It does not bind the GH receptor and does not raise IGF-1, which is the property that originally made it interesting as a weight-management compound without the growth-promoting risks of full GH.

The regulatory status of any drug tells you something concrete: whether the compound has been tested in adequately powered, independently reviewed human trials; whether the manufacturing process meets quality standards; and whether anyone with legal authority has signed off on a risk-benefit calculation. For AOD-9604, the answer across every major jurisdiction is the same. No authority has done that.

This matters more for women than for men for reasons that go beyond general caution. Women considering AOD-9604 are often doing so in the context of post-pregnancy weight retention, perimenopause metabolic changes, or PCOS-related body composition challenges. These are life stages where the consequences of an unregulated drug, including contamination, mislabeling, and hormonal interference, carry added stakes.

The Original Science: What the Research Actually Showed

The peptide was developed by Metabolic Pharmaceuticals in Australia in the 1990s. Animal studies, including the often-cited Heffernan et al. (2001) paper in Endocrinology, showed that AOD-9604 reduced fat mass in obese mice without affecting lean mass or IGF-1 levels, which was a meaningful mechanistic signal. That 2001 study used subcutaneous administration in a rodent obesity model and demonstrated lipolytic activity.

The jump from obese-mouse data to human approval is where the story stalls. Metabolic Pharmaceuticals advanced the compound through Phase IIb and Phase III trials in obese adults, branded as Aethon, in the early 2000s. The Phase IIb METAOD trial and subsequent Phase III work did not demonstrate statistically significant weight loss over placebo at the doses tested. Without efficacy proof in key trials, there was no regulatory submission that could succeed.

Where Female-Specific Trial Data Is Missing

Women were included in the obesity trials but the published data does not report sex-stratified outcomes for weight loss, adverse events, or metabolic markers. This is a documented evidence gap. Hormonal fluctuations across the menstrual cycle affect peptide pharmacokinetics in ways that have never been studied for AOD-9604. Women in perimenopause or using hormonal contraception were not analyzed as subgroups.

The WomanRx evidence-gap framework for unapproved peptides: when a compound has no sex-stratified efficacy data AND no approved indication, the risk-benefit calculation for women cannot be completed. AOD-9604 sits in exactly this position.

FDA Status: The Detailed Picture

AOD-9604 has never been approved by the FDA. It does not appear in Drugs@FDA under any NDA, BLA, or ANDA. It is not on the FDA's list of approved drug products.

The 503A Bulk Compounding Removal

The key regulatory event that changed everything for US-based compounding pharmacies occurred when the FDA evaluated AOD-9604 as a nominee for the 503A bulk drug substances list. The FDA's 503A bulklist process allows certain substances to be compounded even without an approved drug application, provided they meet specific criteria including adequate safety data.

AOD-9604 was nominated but was not placed on the positive list. The FDA's evaluation found insufficient clinical evidence to support inclusion. This means that after the evaluation period, compounding pharmacies operating under 503A cannot legally compound AOD-9604 for human use. Similarly, the 503B outsourcing facility framework, which covers higher-volume compounding, does not include AOD-9604 on its list of bulk drug substances.

What "Unapproved Drug" Means in Practice

An unapproved drug sold or compounded for human use in the US is subject to FDA enforcement. The FDA has the authority to issue warning letters, seize products, and pursue criminal charges against manufacturers and distributors. For individual patients, FDA enforcement action is rare but the quality risk is very real: a product made outside regulated pharmacy standards may contain incorrect concentrations, bacterial contamination, or unlisted ingredients. A 2023 FDA analysis of compounded peptide products found quality failures across multiple unapproved injectable peptides, though the agency has not published a compound-specific failure rate for AOD-9604.

Research vs. Clinical Use

AOD-9604 can be purchased legally in the United States labeled "for research use only" from chemical suppliers. This labeling is not a regulatory loophole that makes the compound safe for injection. Research-use-only reagents are not manufactured under pharmaceutical-grade current Good Manufacturing Practice (cGMP) standards and are not intended for administration to humans.

Global Regulatory Status by Jurisdiction

No country currently has an approved AOD-9604 product for human clinical use.

Australia

Australia is the most frequently misrepresented jurisdiction in AOD-9604 marketing. Metabolic Pharmaceuticals, an Australian company, did receive Therapeutic Goods Administration (TGA) approval for an oral form of AOD-9604 for osteoarthritis under the brand name Aethon in 2014. This approval was narrow, condition-specific, and oral. It was not an approval for injectable use or for weight loss. The company subsequently withdrew the product from the Australian market without completing commercialization. The TGA's ARTG database does not currently list an active registered entry for AOD-9604.

European Union

The European Medicines Agency (EMA) has no European Public Assessment Report (EPAR) for AOD-9604. The compound has not completed the EMA centralized procedure or any national mutual recognition procedure that would allow marketing authorization in EU member states. Compounding under the EU's "magistral formula" exception exists in some member states but requires the prescribing clinician to take personal responsibility for an unlicensed preparation.

Canada

Health Canada has not approved AOD-9604. It is not listed in the Drug Product Database as an authorized drug. It can appear in the Canadian market as an unscheduled research compound, but selling or prescribing it as a therapeutic is not authorized.

United Kingdom

The Medicines and Healthcare products Regulatory Agency (MHRA) has not authorized AOD-9604. Like Canada and the EU, the UK permits unlicensed specials to be prescribed by a clinician for a named patient, but this is a legal mechanism for exceptional clinical need, not a routine prescription pathway.

Pregnancy and Lactation Safety (Required Reading)

AOD-9604 is presumed contraindicated in pregnancy. There are no human pregnancy data. No animal reproductive toxicology studies have been published in the peer-reviewed literature. The FDA has not assigned a formal pregnancy category because the drug is unapproved, but the absence of safety data is itself the safety signal.

What We Know and What We Do Not

Peptide drugs can cross the placenta depending on molecular weight and transporter expression. AOD-9604 has a molecular weight of approximately 1,815 daltons. At this size, passive placental transfer is possible though not certain. No study has measured placental transfer of AOD-9604 in any species.

GH-axis peptides affect fetal growth. While AOD-9604 does not bind the GH receptor in the same way as full GH, its lipolytic mechanism involves adrenergic receptors and beta-3 receptor pathways. Altering maternal fat metabolism during organogenesis carries theoretical risks that have not been evaluated.

Lactation

There are no data on AOD-9604 transfer into breast milk. Peptides of this size are sometimes degraded in the infant GI tract and may have low oral bioavailability in the nursing infant, but this reasoning is speculative and not specific to AOD-9604. Use during breastfeeding cannot be considered safe.

Contraception Requirements

Because AOD-9604 is often used for weight management, and because weight loss itself affects hormonal contraceptive efficacy in some circumstances, women of reproductive age using this compound should use highly effective contraception. The reasoning here is not that AOD-9604 is a known teratogen (there is simply no data to determine this) but that an uncharacterized compound should never be present during a planned or unplanned pregnancy.

Women with PCOS who are trying to conceive and who have been recommended AOD-9604 by online providers for insulin resistance should know: there is no trial evidence supporting this use, the compound is unregulated, and the safety profile in early pregnancy is completely unknown.

Women-Specific Conditions Where AOD-9604 Is Marketed Off-Label

PCOS and Insulin Resistance

PCOS affects 8 to 13 percent of reproductive-age women worldwide, and insulin resistance is a core feature in the majority. AOD-9604 is promoted in some wellness communities as a way to improve body composition and insulin sensitivity in women with PCOS. There is no published randomized controlled trial in women with PCOS. The mechanistic rationale, that reducing adiposity improves insulin signaling, is plausible but does not validate AOD-9604 specifically over proven interventions like metformin, lifestyle modification, or semaglutide.

Perimenopause and Menopause

The perimenopausal transition brings progressive changes in body fat distribution, particularly visceral fat accumulation, that are driven by estrogen decline. Research published in Menopause consistently shows that this redistribution is not simply a caloric problem but a hormonal one. AOD-9604 is marketed to perimenopausal women as a way to target this visceral fat without hormones.

The evidence for this use does not exist in peer-reviewed literature. Perimenopausal women also have fluctuating estrogen levels that affect peptide pharmacokinetics in ways that have never been studied for this compound.

Postpartum Weight Retention

Postpartum weight retention is a genuine clinical concern. Approximately 20 percent of women retain more than 5 kilograms one year after delivery, and this retained weight is associated with long-term cardiometabolic risk. AOD-9604 is circulating in postpartum wellness spaces as a faster solution than dietary change alone.

Postpartum and breastfeeding women should not use AOD-9604. There is no lactation safety data. The postpartum hormonal environment, with prolactin dominant and estrogen low, has never been studied as a background for AOD-9604 pharmacology.

Who This Is Right For and Who Should Avoid It

Who Should Not Use AOD-9604

• Women who are pregnant or trying to conceive. No safety data exists and the risk is unquantifiable.
• Women who are breastfeeding. Milk transfer is unknown.
• Women with any history of pituitary tumors or GH-axis disorders. Peptides acting near the GH axis warrant extra caution in this group.
• Women purchasing injectable products labeled "research use only." These are not made to pharmaceutical standards.
• Women in any jurisdiction where compounding AOD-9604 is not legally authorized, including the United States.

Who Might Appear to Be a Candidate but Still Lacks Evidence

Women with obesity, PCOS-related metabolic dysfunction, or postmenopausal visceral adiposity are the populations most aggressively targeted by AOD-9604 marketing. The conditions are real and the unmet need is real. The compound, however, has not demonstrated efficacy in a completed, published, approved clinical program for any of these groups. Semaglutide 2.4 mg (Wegovy), by comparison, reduced body weight by 15.2 percent in the STEP 1 trial, with a well-characterized safety database and FDA approval. The comparison is not to shame patients for curiosity about AOD-9604. It is to clarify what an approved drug looks like compared to what AOD-9604 is.

Quality and Safety Concerns with Unregulated Peptide Products

When a drug is not approved and is not manufactured under cGMP, quality is not guaranteed.

Contamination and Concentration Errors

Independent testing of compounded peptides in the United States has found products with incorrect concentrations, bacterial endotoxins, and unidentified impurities. The FDA's own sampling programs have flagged compounded injectables for these issues. Injecting a contaminated product carries risks of local infection, systemic infection, and immune reactions that bear no relationship to the intended pharmacology of AOD-9604.

No Pharmacovigilance System

Approved drugs are monitored through post-market pharmacovigilance: FDA's Sentinel System, MedWatch adverse event reporting, and REMS programs where relevant. AOD-9604 sits outside all of these systems. Adverse events are not collected systematically. Women who experience side effects have no structured reporting mechanism, and the absence of a safety signal in the published literature does not mean the compound is safe. It means it is unmonitored.

A direct quotation from FDA's compounding guidance is relevant here: "FDA-approved drugs have been evaluated for safety and effectiveness, whereas compounded drugs have not been evaluated or approved by FDA."

The Honesty About Evidence Gaps

The published Phase IIb and Phase III obesity trials for AOD-9604 were completed but the full datasets were never published in peer-reviewed journals in a form that allows independent analysis of sex-stratified outcomes, adverse event profiles by hormonal status, or long-term follow-up beyond 24 weeks. This is a meaningful evidence gap. Women considering this compound are being asked to accept a risk-benefit calculation where the "benefit" side of the equation was never adequately proven in humans, and the "risk" side has never been evaluated in women at any specific life stage.

The Endocrine Society's position on unapproved peptides, stated in their 2023 clinical practice guidance, notes that "the evidence base for most peptide compounds sold through wellness channels does not meet the standard required for clinical recommendation."

Practical Guidance: Questions to Ask Any Provider Who Recommends AOD-9604

If a telehealth provider, med spa, or compounding pharmacy is recommending AOD-9604, ask these specific questions before accepting a prescription or purchasing a product.

First: Is the compounding pharmacy licensed in your state and operating under a valid 503A registration? Can they provide a certificate of analysis for the specific batch?

Second: What is the legal basis for prescribing an unapproved compound in your state? Which state pharmacy board regulations govern this prescription?

Third: What monitoring will be in place? Will you track liver enzymes, metabolic markers, or any parameter that could detect harm?

Fourth: What happens if you experience an adverse event? Is there a MedWatch reporting process?

A provider who cannot answer these questions with specifics is not practicing within a framework that protects you.

The Regulatory Path Forward

AOD-9604 is not categorically a dangerous compound. The animal data suggested a real lipolytic mechanism. The human trials failed on efficacy, not on a dramatic safety signal. The path to legitimate clinical use would require a sponsor to file an IND with the FDA, complete Phase II and Phase III trials with adequate sex stratification and hormonal subgroup analysis, demonstrate efficacy, and submit an NDA.

That process has not been initiated by any publicly disclosed sponsor. Until it is completed, AOD-9604 remains an unapproved drug with no legal pathway to human use in the United States, no approved indication in any jurisdiction, and no adequate human safety data for women at any life stage.

If you are looking for evidence-based options for the underlying concerns that lead women to AOD-9604, including PCOS, perimenopausal weight gain, postpartum metabolic changes, or obesity, the WomanRx clinical team works with GLP-1 medications, metformin, hormonal therapy, and structured nutrition approaches that have completed the regulatory process. Your starting point should be a provider who can prescribe from the approved list first.